{"id":130921,"date":"2022-07-01T11:48:31","date_gmt":"2022-07-01T15:48:31","guid":{"rendered":"https:\/\/44.250.171.167\/?p=130921"},"modified":"2022-10-06T04:41:56","modified_gmt":"2022-10-06T08:41:56","slug":"research-summary-dr-lal-path-labs-limited-q4-fy-2022","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/research-summary-dr-lal-path-labs-limited-q4-fy-2022\/","title":{"rendered":"Research Summary Dr Lal PathLabs Limited Q4 FY 2022"},"content":{"rendered":"\n

Overview<\/u><\/strong><\/p>\n\n\n\n

Dr Lal PathLabs Limited\u00a0is an Indian diagnostic company. It was incorporated in 1949. The headquarters is situated in Delhi, India. It has 70+ years of experience in diagnostics. It has successfully served 100 million patients in the last 5 years.\u00a0 It has 277 clinical labs, including the National Reference Lab at Delhi and Regional Reference lab in Kolkata. It has 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points(PUPs).<\/p>\n\n\n\n

The company has a wide range of portfolios. It includes pathology, radiology and cardiology tests. The customers of the company are individual patients and hospitals. It has its presence in large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. <\/p>\n\n\n\n

Understanding the Business Model<\/u><\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Financial Snapshot (Figures in Rs Crores)<\/u><\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Operating Revenue increased by 12.7% to Rs. 485.5 Crores. The EBITDA stood at Rs 130.7 Crores. The PBT is Rs 83.5 Crores in Q4 FY22. PAT is Rs 62.1 Crores in Q4 FY22. For FY22, Dr Lal PathLabs Limited has served 27.3 million patients with a revenue of Rs 2,087 crores. In Q4 FY22 the non-COVID revenue is Rs 419.7 crores with a registered growth of 12.2%. For FY22, non-COVID revenue is Rs 1,691 crore, registering a growth of 34.5%.Covid and Allied contributed 13.6% to revenue in Q4 FY22.<\/p>\n\n\n\n

Operating Highlights for Last 4 years<\/u><\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Outlook of the company<\/u><\/strong><\/p>\n\n\n\n

Dr Lal PathLabs Limited\u00a0has decided the expansion of Bangalore Reference Labs. It has decided to open up new satellite labs in South India. The company has enabled digital tools and technologies to serve the patients. The vision of the company is to drive growth through patient and partner experience, leveraging digital technologies and improving geographical reach and test portfolio.<\/p>\n\n\n\n

Analysis of Ratio\u2019s for past 5 years<\/u><\/strong><\/p>\n\n\n\n

 <\/td>FY 18<\/td>FY 19<\/td>FY 20<\/td>FY 21<\/td>FY 22<\/td><\/tr>
ROCE%<\/td>37.9<\/td>34.78<\/td>32.94<\/td>36.03<\/td>32.6<\/td><\/tr>
ROE%<\/td>25.32<\/td>23.76<\/td>23.74<\/td>26.89<\/td>26.39<\/td><\/tr>
ROA%<\/td>311.72<\/td>359.22<\/td>21.28<\/td>25.65<\/td>16.74<\/td><\/tr>
Debt\/Equity<\/td>0<\/td>0<\/td>0<\/td>0<\/td>0.24<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

According to industry perspective, the company needs to improve the ratios. There is a sharp fall in ratio in FY22. The company has zero debt in last 4 years. However, in FY22 it has increased to 0.24.
<\/p>\n\n\n\n

SWOT analysis<\/u><\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n\n\n

Strength-<\/u><\/strong> There is an improvement in Net Profit quarter over quarter. The company has low debt as per balance sheet.  The company has a strong cash generating ability from its core business. There is a zero promoter\u2019s pledge.<\/p>\n\n\n\n

Weakness-<\/u><\/strong>The business includes lots of regulatory hurdles as it is a healthcare business.<\/p>\n\n\n\n

Opportunity- <\/u><\/strong>The companyis expanding itself in Southernand Western India.<\/p>\n\n\n\n

Threats –<\/u><\/strong>The company has a regional concentration in revenue. The revenue mainly comes from the Northern region of India. In order to grow further the company should focus more on Merger & Acquisitions. There is a stiff competition from diagnostic companies and Ecommerce players. The business is dependent on doctor\u2019s referral.<\/p>\n\n\n\n

Comparative Analysis<\/u><\/strong><\/p>\n\n\n\n

Dr Lal Path<\/strong>Labs<\/td>Metropolis<\/strong><\/td>Thyrocare<\/strong><\/td><\/tr>
Incorporated in 1949<\/td>Established in 1980<\/td>Established in 1996<\/td><\/tr>
One of the largest diagnostics  chain<\/td>One of the largest diagnostics  chain<\/td>200+ test<\/td><\/tr>
200+ clinical labs , 455 test panel<\/td>Present across 19 states and 210 cities<\/td> <\/td><\/tr>
3000+ patient Service centre<\/td>Received 10 million patients in FY 20 and completed 19.6 million tests<\/td>50 profiles comprising test for preventive care and wellness<\/td><\/tr>
1961 radiology & cardiology test<\/td>10000+ patient touch points<\/td> <\/td><\/tr>
Market Cap of Rs 20000 crores<\/td>Market Cap of Rs 11000 crores<\/td>Market Cap of Rs 5000 crores<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Industry Analysis<\/u><\/strong><\/p>\n\n\n\n

The growth of the diagnostics industry is solely dependent on technological advancements in the healthcare industry, and doctors relying more on evidence-based treatment. Moreover, the labs which are attached to the hospitals generate more revenue. They emphasize more on patient count compared to the quality of the test. To survive in this industry Dr Lal PathLabs is concentrating on enhancing its product mix, geographic mix and channel mix.<\/p>\n\n\n\n

Strategy for Future Growth with Digital Innovation<\/u><\/strong><\/p>\n\n\n\n

Dr Lal PathLabs Limited\u00a0has made Self Registration Kiosk for patients and also Self Report printing Kiosks for 24 by 7. It has introduced Online test \/ health package booking. Launched Phlebo Mobile App for home collection booking along with route plan. If the patient has undergone any test from Dr Lal PathLabs Limited\u00a0he can view and download current and historical test reports directly.<\/p>\n\n\n\n

Projects in Pipeline<\/u><\/strong>: Managing Director, Dr Lal PathLabs Pvt Ltd, spoke about a pilot project to transport blood samples via drones. He even emphasized that it will be more beneficial in the hilly region where it takes more time to bring the sample. This facility can be used as an emergency for such cases.<\/p>\n","protected":false},"excerpt":{"rendered":"

Overview Dr Lal PathLabs Limited\u00a0is an Indian diagnostic company. It was incorporated in 1949. The headquarters is situated in Delhi, India. It has 70+ years of experience in diagnostics. It has successfully served 100 million patients in the last 5 years.\u00a0 It has 277 clinical labs, including the National Reference Lab at Delhi and Regional […]<\/p>\n","protected":false},"author":1796,"featured_media":58681,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6352,9908],"tags":[8665,8975],"class_list":["post-130921","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-summary","category-research-tear-sheet","tag-diagnostics","tag-diagnostics-research"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":132307,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-limited-research-report\/","url_meta":{"origin":130921,"position":0},"title":"Dr Lal PathLabs Limited Research Report","author":"sreerupa","date":"August 3, 2022","format":false,"excerpt":"Stock Data Ticker: LALPATHLAB Exchange :\u00a0\u00a0\u00a0\u00a0 NSE BSE:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 539524 Industry:\u00a0\u00a0\u00a0\u00a0\u00a0 Diagnostic Price Performance Last 7 days\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 8.70% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -38.28% Last 12 months\u00a0\u00a0\u00a0\u00a0 -39.34% The stock is showing a downward trend due to Tata 1mg's disruption expectations in the diagnostic business. It is expected that due to the intervention of Tata's\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145759,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-dr-lal-pathlabs-limited-for-q4-fy23\/","url_meta":{"origin":130921,"position":1},"title":"Earnings Summary Of Dr. Lal Pathlabs Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 11, 2023","format":false,"excerpt":"Dr. Lal Pathlabs Limited is a healthcare diagnostics service provider headquartered in India. The company offers a wide range of diagnostic and related healthcare tests and services, including pathology, microbiology, imaging, and genetic testing. Dr. Lal Pathlabs operates through a network of over 200 clinical laboratories and more than 2,800\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163744,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1fy25-29-rise-in-profits\/","url_meta":{"origin":130921,"position":2},"title":"Dr Lal Pathlabs Ltd Q1FY25; 29% rise in Profits","author":"Chirag Gupta","date":"August 9, 2024","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169027,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4fy25-81-rise-in-profits\/","url_meta":{"origin":130921,"position":3},"title":"Dr Lal Pathlabs Ltd Q4FY25; 81% rise in Profits","author":"Divyansh_Kasana","date":"July 7, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":140051,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":130921,"position":4},"title":"Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 3, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the revenue and EBITDA for Suburban for 3Q23. C. A. Ved Prakash CFO said Suburban had revenue of INR37 crores, with INR35 crores from non-COVID and the rest from\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172310,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-q2-fy26-earnings-results\/","url_meta":{"origin":130921,"position":5},"title":"Dr Lal Pathlabs Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 11, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lal Pathlab Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1796"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=130921"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130921\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/58681"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=130921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=130921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=130921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}